Версия для слабовидящих:
Размер шрифта:

The 4th International Cancer Symposium, October 2-4, 2019, Lyon, France

  • Main
  • News
  • The 4th International Cancer Symposium, October 2-4, 2019, Lyon, France
The symposium was attended by 550 people from France, Germany, Belgium, the USA, Great Britain and other countries of the world. This Symposium included four research areas: stem cells and tumor cell plasticity, tumor microenvironment and immunity, ribosomes and cancer, and oncogenetics. The Oncogenetics section was dedicated to the memory of Professor Gilles Thomas, a renowned scientist in the study of the genetic predisposition to cancer and the founder of the school of oncogenetics in France. The prominent oncologist, Professor Robert Weinberg, Head of the Cancer Biology Laboratory at the Whitehead Institute for Biomedical Research (USA) and one of the authors of widely known studies entitled “Hallmarks of Cancer” (Cell 2000) and “Hallmarks of Cancer: The Next Generation ”(Cell 2011) took an active part at the Symposium. In his lecture, Robert Weinberg emphasized that tumors undergoing an epithelial-mesenchymal transition and exhibiting a mesenchymal phenotype are resistant to immune therapy based on control point inhibitors. The report of Dr. Frederic De Sauvage from Genetech Inc. company (USA) focused on tumor plasticity as a mechanism of resistance to targeted therapy.  Dr. Michael F. Clarke from Stanford Institute for Stem Cells and Regenerative Medicine (USA) made an oral presentation on the heterogeneity of tumor stem cells and its role in metastasis. Prof. Thomas Brabletz from the University of Erlangen-Nuremberg (Germany) reported on the phenotypic variability of the epithelial-mesenchymal transition and the crucial role of ZEB1 protein in tumor progression.  
Evgeny Denisov, PhD, Head of the laboratory of Tumor Progression Biology of Cancer Research Institute, presented poster-teaser and made oral presentation titled “Mutational landscape of breast cancer with various invasive growth options”. In his lecture, he emphasized that breast cancer with individual invasion, the most aggressive type of invasive growth when single invading tumor cells migrate and infiltrate neighboring tissue, is associated with mutations in genes that negatively regulate the activity of small Rho GTPases. The latter are key regulators of cell migration and invasion. The presented results were obtained with the support of the Russian Federal Property Fund and CNRS (project No. 18-515-16002).